OncoSec Medical Finds SBIR Funding

San Diego-based OncoSec Medical, which is developing DNA-based intratumoral cancer immunotherapies, said this morning that it has received a Phase I, Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH). The SBIR award is worth $163,000, and will go towards the evaluation and development of novel electroporation technologies. OncoSec said the award came in conjunction with Old Dominion University.